OR-1855

OR-1855, an active metabolite of Levosimendan (HY-14286), has effect on myometrial contractility. OR-1855 exerts anti-inflammatory effects by inhibiting IL-1β-induced ROS formation and NAD (P) H oxidase-dependent superoxide radical generation in HUVECs. OR-1855 inhibits IL-1β-induced phosphorylation p38 MAPK, ERK1/2, c-Jun and JNK in HUVECs. OR-1855 can be used for the study of inflammation[1][2][3].

Product Specifications

CAS Number

[101328-85-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Drug Metabolite; ERK; p38 MAPK; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/or-1855.html

Concentration

10mM

Purity

99.78

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C[C@@H](C)C(C2=CC=C(N)C=C2)=NN1

Molecular Formula

C11H13N3O

Molecular Weight

203.25

Precautions

H302, H315, H319, H335

References & Citations

[1]Banfor PN, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008 Jan;294 (1) :H238-48.|[2]Mark P. Hehir, et al. 487: OR-1855, a levosimendan metabolite with an effect on human myometrial contractility.December 2009Volume 201, Issue 6, Supplement, Pages S182-S183.|[3]Kipka H, et al. The Effects of the Levosimendan Metabolites OR-1855 and OR-1896 on Endothelial Pro-Inflammatory Responses. Biomedicines. 2023 Mar 16;11 (3) :918.